Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 42.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,737 shares of the biotechnology company’s stock after selling 16,514 shares during the period. Victory Capital Management Inc.’s holdings in Arrowhead Pharmaceuticals were worth $427,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinion Investment Advisors LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $1,410,000. Charles Schwab Investment Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,017,720 shares of the biotechnology company’s stock worth $19,133,000 after buying an additional 10,785 shares during the period. Fisher Asset Management LLC raised its position in Arrowhead Pharmaceuticals by 16.9% during the 4th quarter. Fisher Asset Management LLC now owns 142,939 shares of the biotechnology company’s stock worth $2,687,000 after buying an additional 20,679 shares during the last quarter. Amalgamated Bank lifted its stake in Arrowhead Pharmaceuticals by 3.6% during the 4th quarter. Amalgamated Bank now owns 56,722 shares of the biotechnology company’s stock valued at $1,066,000 after acquiring an additional 1,957 shares during the period. Finally, Handelsbanken Fonder AB boosted its holdings in shares of Arrowhead Pharmaceuticals by 15.4% in the 4th quarter. Handelsbanken Fonder AB now owns 41,200 shares of the biotechnology company’s stock valued at $775,000 after acquiring an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 2.1 %

ARWR stock opened at $14.80 on Friday. The firm has a market cap of $2.03 billion, a PE ratio of -2.86 and a beta of 0.92. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm’s fifty day moving average is $18.58 and its 200 day moving average is $19.90. Arrowhead Pharmaceuticals, Inc. has a one year low of $14.23 and a one year high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Ratings Changes

ARWR has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Piper Sandler cut their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Finally, StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $41.44.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares of the company’s stock, valued at $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 12,563 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $19.59, for a total transaction of $246,109.17. Following the transaction, the chief executive officer now directly owns 3,775,772 shares in the company, valued at approximately $73,967,373.48. The trade was a 0.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 301,730 shares of company stock valued at $5,352,844 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.